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Summary The expression of three epidermal growth factor (EGF)-related peptides, transforming growth
factor a (TGF-a), amphiregulin (AR) and cripto-l (CR-1), was examined by immunocytochemistry (ICC) in
68 primary infiltrating ductal (IDCs) and infiltrating lobular breast carcinomas (ILCs), and in 23 adjacent
non-involved human mammary tissue samples. Within the 68 IDC and ILC specimens, 54 (79%) expressed
immunoreactive TGF-a, 52 (77%) expressed AR and 56 (82%) expressed CR-1. Cytoplasmic staining was
observed with all of the antibodies, and this staining could be eliminated by preabsorption of the antibodies
with the appropriate peptide immunogen. Cytoplasmic staining with all of the antibodies was confined to the
carcinoma cells, since no specific immunoreactivity could be detected in the surrounding stromal or endothelial
cells. In addition to cytoplasmic reactivity, the AR antibody also exhibited nuclear staining in a number of the
carcinoma specimens. No significant correlations were found between the percentage of carcinoma cells that
were positive for TGF-a, AR or CR-1 and oestrogen receptor status, axillary lymph node involvement,
histological grade, tumour size, proliferative index, loss of heterozygosity on chromosome 17p or overall
patient survival. However, a highly significant inverse correlation was observed between the average percentage
of carcinoma cells that expressed AR in individual tumours and the presence of a point-mutated p53 gene.
Likewise, a significantly higher percentage of tumour cells in the ILC group expressed AR as compared with
the average percentage of tumour cells that expressed AR in the IDC group. Of the 23 adjacent, non-involved
breast tissue samples, CR-1 could be detected by ICC in only three (13%), while TGF-a was found in six
(26%) and AR in ten (43%) of the non-involved breast tissues. These data demonstrate that breast carcinomas
express multiple EGF-related peptides and show that the differential expression of CR-1 in malignant breast
epithelial cells may serve as a potential tumour marker for breast cancer.
A number of different growth factors have been demon-
strated to be synthesised by normal and malignant mammary
epithelial cells (Davidson & Lippman, 1989; Salomon et al.,
1992). These locally acting peptides may be important in
regulating the growth of mammary epithelial cells through
potential autocrine, juxtacrine and/or paracrine pathways
(Aaronson, 1991; Sporn & Roberts, 1992). Epidermal growth
factor (EGF) and peptides that are structurally related to
EGF, such as transforming growth factor a (TGF-cz), are
potent mitogens for mammary epithelial cells (Ciardiello et
al., 1990a; Osborne & Arteaga, 1990). These peptides bind to
the EGF receptor and activate its intrinsic tyrosine kinase
activity (Massague, 1990; Salomon et al., 1990). TGF-o has
been detected in approximately 40-70% of primary human
breast carcinomas, whereas EGF receptor expression occurs
in nearly 50% of human breast tumours (Bates et al., 1988;
Travers et al., 1988; Barrett-Lee et al., 1990; Ciardiello et al.,
1990a; Klijn et al., 1992; Dublin et al., 1993). Coexpression
of TGF-o and EGF receptor occurs in a majority of those
breast tumours that are expressing either protein, suggesting
that a potential autocrine or juxtacrine loop may exist in vivo
in a subset of human breast tumours (Bates et al., 1988;
Travers et al., 1988; Barrett-Lee et al., 1990). EGF receptor
status is also an important independent prognostic factor in
human breast cancer (Sainsbury, 1990; Klijn et al., 1992).
High levels of EGF receptor expression are generally
associated with tumours that have higher proliferative rates,
with axillary lymph node involvement and with low disease-
free or overall survival (Nicholson et al., 1988; Sainsbury,
1990; Gasparini et al., 1992). The activation of different
proto-oncogenes and/or loss of expression of specific tumour-
suppressor genes also frequently occurs in primary human
breast tumours (Callahan & Campbell, 1989). These genetic
alterations may affect the expression of and/or response to
growth factors and can have a negative impact on overall
patient survival (Aaronson, 1991; Salomon et al., 1992). In
this respect, inactivation of the p53 tumour-suppressor gene
on chromosome 17p by point mutations and/or loss of
heterozygosity (LOH) occurs in approximately 30-50% of
primary human breast carcinomas (Callahan & Campbell,
1989; Biartek et al., 1990; Horak et al., 1991; Osborne et al.,
1991; Mazars et al., 1992; Poller et al., 1992). There is
evidence demonstrating that the wild-type p53 gene encodes a
nuclear phosphoprotein that functions as a transcription fac-
tor which can negatively regulate cell proliferation and which
is involved in the pathway for other growth factor-controlled,
cell cycle-related genes (Ullrich et al., 1992).
TGF-a is only one of several proteins that can bind to the
EGF receptor (Massague, 1990; Salomon et al., 1990). Other
newly discovered members of the EGF/TGF-a family of
proteins include heparin-binding EGF-like growth factor
(HB-EGF), amphiregulin (AR) and cripto-I (CR-1, or
teratocarcinoma-derived growth factor 1) (Ciccodicola et al.,
1989; Plowman et al., 1990; Higashiyama et al., 1992). AR is
a 78 or 84 amino acid glycosylated protein that is initially
synthesised as a 252 amino acid transmembrane precursor
(Plowman et al., 1990). Unlike EGF or TGF-a but similar to
HB-EGF (Higashiyama et al., 1992), AR can bind to heparin
and has a hydrophilic 43 amino acid amino-terminal exten-
sion that contains at least two presumptive motifs which are
similar to the nuclear localisation sequences associated with
DNA-binding proteins (Plowman et al., 1990). AR can bind
to the EGF receptor, but with a lower affinity than EGF, can
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activate the EGF receptor tyrosine kinase and can transac-
tivate the c-erbB-2 tyrosine kinase in several human breast
and ovarian epithelial cell lines (Plowman et al., 1990; John-
son et al., 1993). Exogenous AR can either stimulate or
inhibit the growth of different types of normal and malignant
human epithelial cells, depending upon the concentration,
presence of other growth factors and nature of the target cell
(Plowman et al., 1990; Johnson et al., 1991, 1992; Normanno
et al., 1992; Li et al., 1992). AR is expressed in and is able to
function as an autocrine growth factor for several human
mammary epithelial cell strains and for c-Ha-ras- and c-erbB-
2-transformed MCF-1OA human mammary epithelial cells
(Li et al., 1992; Normanno et al., 1992). CR-1 is a 188 amino
acid protein that, unlike other members of the EGF/TGF--
family, lacks a hydrophobic signal peptide and transmemb-
rane domain, but which contains a central region of approx-
imately 37 amino acids that shares structural homology with
peptides within this family (Ciccodicola et al., 1989; Dono et
al., 1991). Although a recombinant or naturally occurring
CR-1 protein has not yet been obtained to ascertain its
biological properties, overexpression of the human CR-I gene
can lead to the in vitro transformation of mouse NIH3T3
fibroblasts or mouse NOG-8 mammary epithelial cells,
demonstrating that CR-1, like TGF-a and AR, can function
as an autocrine growth factor and/or dominantly transform-
ing oncogene (Ciccodicola et al., 1989; Ciardiello et al.,
1990b, 1991a; Jhappan et al., 1990; Matsui et al., 1990). In
addition, CR-1 is expressed in a majority of human colorec-
tal and gastric carcinoma cell lines and tumours (Ciccodicola
et al., 1991b; Kuniyasu et al., 1991; Saeki et al., 1992).
TGF-a, AR and CR-1 mRNA transcripts are expressed in
a number of different human breast cancer cell lines (Bates et
al., 1988; Davidson & Lippman, 1989; Murphy & Dotzlaw,
1989; Plowman et al., 1990; Normanno et al., 1993). Since
there is little or no information on the frequency and level of
expression of AR or CR-1 in primary human breast lesions,
we have analysed a small panel of infiltrating human breast
carcinomas and non-involved breast tissues adjacent to car-
cinomas for TGF-x, AR and CR-1 expression. Immunocyto-
chemistry (ICC) using peptide-specific polyclonal antibodies
that are capable of detecting these proteins in formalin-fixed,
paraffin-embedded tissues was used to ascertain if these pep-
tides can be localised in mammary epithelial cells and to
determine if there is any differential expression of these pro-
teins between non-involved and malignant breast tissues.
Materials and methods
Human breast tissues
Paraffin blocks of formalin-fixed tissue and frozen tissue
samples that were obtained from 68 primary infiltrating
breast carcinomas with 23 cases of non-involved breast tissue
were collected at the S. Giovanni Vecchio Hospital, Turin,
Italy. A portion of each tumour specimen was frozen in
liquid nitrogen at - 70°C until extraction of genomic DNA
or before evaluation of the labelling index by bromodeoxy-
uridine (BrdU) incorporation. Patients were graded histo-
pathologically according to the Bloom and Richardson
(1957) method and by the UICC TNM (tumour, nodes,
metastases) staging system.
Polyclonal antibodies
Rabbit antibody R9 was generated against recombinant
human TGF-o that had been conjugated to keyhole limpet
haemocyanin (KLH) as previously described (Finzi et al.,
1991). The anti-AR antibody (AR-Ab-1) was raised against a
19-mer synthetic peptide that corresponds to residues 8-26
in the human AR protein as previously described (Johnson et
al., 1991, 1992). The specificity and reactivity of the affinity-
purified AR-Ab-1 immunoglobulin G (IgG) was evaluated as
previously described (Johnson et al., 1991, 1992). The AR-
Ab-i antibody can detect recombinant human AR in an
enzyme-linked immunosorbent assay (ELISA). In addition,
the AR-Ab-l IgG is able to detect a specific M,
18,000-25,000 glycoprotein in the conditioned medium
obtained from 12-O-tetradecanoylphorbol-13-acetate (TPA)-
treated MCF-7 human breast cancer cells and does not react
with either EGF or TGF-a (Johnson et al., 1991). The anti-
CR-1 antibody (CR-1 Ab) was generated against a 17-mer
synthetic peptide that corresponds to amino residues 97-113
in the human CR-1 protein and that represents the carboxy
terminus of the 37 amino acid EGF-like region as previously
described (Saeki et al., 1992). The CR-1 Ab is able to detect
an M, 32,000 MS2-CR-I fusion protein derived from
Escherichia coli, an M, 28,000 thrombomodulin signal pep-
tide CR-1 protein derived from human CR-1-transfected
CHO cells and a specific Mr 36,000 endogenous CR-1 protein
in several human tumour cell lines that express the 2.2 kb
CR-1 mRNA following Western blot analysis (Saeki et al.,
1992; R. Brandt et al., in preparation). CR-1 Ab does not
recognise either human TGF-a or AR in an ELISA, but
reacts strongly with the 17-mer CR-1 peptide immunogen.
Immunocytochemistry and evaluation ofimmunoperoxidase
staining
Paraffin-embedded tissue sections (5 jim) were deparaffinised
in xylene and rehydrated in a graded series of ethanol. The
slides were then treated for 30 min at 20°C with methanol
containing 0.3% hydrogen peroxide to block any endogenous
peroxidase activity. After several washes with phosphate-
buffered saline (PBS), the sections were incubated for 45 min
with 10% goat serum, washed with PBS and incubated for
12 h with the appropriate primary antibody at 4°C. Sections
were then washed three times with PBS and treated with
secondary biotinylated goat anti-rabbit IgG (1:200 dilution,
Vectastain AC kit; Vector Laboratory, Burlingame, CA,
USA) for 30 min. Following several washes with PBS, the
slides were reacted for 30 min with avidin dehydrogenase-
biotinylated horseradish peroxidase H complex, rinsed twice
in PBS and incubated for 2 min in 0.05% diaminobenzidine
and in 0.01% hydrogen peroxide. The slides were then rinsed
in distilled water, counterstained with haematoxylin and
mounted. The anti-TGF-a R9 primary antibody was utilised
at a 1:200 dilution. In some cases, the R9 antibody was
preabsorbed with 10jgmlm' human TGF-a (Bachem, Tor-
rance, CA, USA) for 2 h at 37°C. The AR-Ab-I IgG was
used at 0 lagml-', which in some instances was preabsorbed
with 20fig ml-' 19-mer AR synthetic peptide for 2 h at 37°C.
The CR-I Ab was utilised at a 1:400 dilution and, in some
cases, was preabsorbed with 20 ig ml1' 17-mer CR-I syn-
thetic peptide for 2 h at 37C. Slides were graded for staining
specificity and intensity and for the percentage of
immunopositive cells as previously described (Johnson et al.,
1991; Saeki et al., 1992). Non-specific staining was evaluated
for each specimen using either a similar concentration or
dilution of preimmune rabbit serum or IgG, or by absorbing
the primary antibody with the appropriate peptide
immunogen. The number of immunopositive cells per slide
was stratified into three groups based upon the percentage of
positive cells: group 1, <30%; group 2, 30-60%; and group
3, >60%.
For analysing proliferation in tumour specimens, frozen
5 jim sections which were obtained in parallel with the
formalin-fixed sections were incubated with a 1:50 dilution of
Ki-67 monoclonal antibody (Dakopatts, UK) for 60 min.
The slides were then washed several times with PBS, reacted
with a 1:200 dilution of biotinylated horse anti-mouse IgG
for 30 min, washed with PBS and stained with avidin
dehydrogenase-biotinylated horseradish peroxidase H com-
plex for 30 min. Nuclei that were stained with the Ki-67
antibody were counted in each specimen and quantitated as a
fraction of the total number of cells in each sample. Approxi-
mately 500 tumour cells were screened for each specimen,
and values were expressed as a percentage of positively
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determine the median cut-off point, 9.0%, for Ki-67 nuclear
staining. Using this value, tumours were classified in either a
high or low index rank.
Oestrogen receptor (ER) assay
Cytosolic ER was assayed by the dextran-coated charcoal
(DCC) method as previously described (Merlo et al.,
1992).
Southern blot analysis and DNA probes
High molecular weight DNA was extracted and blotted as
previously described (Merlo et al., 1992). The DNA was
immobilised by UV cross-linking followed by prehybridisa-
tion and hybridisation with the following 32P-labelled DNA
probes: pYNZ22.1/D17S30 marker probe (ATCC no. 57575
probe, Rockville, MD, USA) (Osborne et al., 1991; Merlo et
al., 1992) and the probe p144D6 (Merlo et al., 1992).
Single-strand conformation polymorphism (SSCP) analysis of
genomic and cDNAforp53point mutations
The polymerase chain reaction (PCR)/SSCP method was
modified to screen for point mutations in the p53 gene as
previously described (Osborne et al., 1991). Genomic DNA/
PCR fragments of 438 bp spanning exons 5 and 6 or 670 bp
containing exons 7 and 8, and cDNA/PCR fragments span-
ning exons 4-7 (codons 242-327) or exons 7-9 (codons
242-327) were amplified using 100 ng of genomic DNA or
250 ng of random-primed cDNA as templates and 0.5fil of
[32P]dCTP (Amersham, Arlington Heights, IL, USA) in 10 ml
reaction volumes. To localise possible point mutations to a
specific exon, 1 il of the PCR product was digested with AatI
(USB, Cleveland, OH, USA) for the exon 5/6 fragment, or
DraI (Bethesda Research Laboratory, Gaithersburg, MD,
USA) for the exon 7/8, and AlwNI (New England Biolabs,
Beverly, MA, USA) for the cDNA/PCR product. The reac-
tion was diluted 1:5 with loading buffer (95% formamide,
2 mM EDTA, pH 8.3). Two microlitres of each diluted sam-
ple was denatured (90°C for 5 min) and loaded onto a 6%
non-denaturing acrylamide gel in 89 mM Tris-borate, 2 mM
EDTA, pH 8.3, and electrophoresed for 5 h at 4°C at 25 W.
The gels were then dried and exposed to X-ray film.
BrdU incorporation
In addition to monitoring for Ki-67 labelling of nuclei, the
proliferation index was also assessed by measuring the levels
of incorporation of BrdU (0.1 mM) into fresh tumour
fragments from each specimen after a 3 h incubation in
short-term tissue culture as previously described (Merlo et
al., 1992). Approximately 500 tumour cells were screened for
each specimen and values were expressed as a percentage of
positively stained nuclei. A panel of 700 breast tumours was
used to determine the median cut-off point, 7.0%, for BrdU
incorporation. Using this value, tumours were classified in
either a high or low proliferation index rank.
Statistical analysis
The tests of significance were the Wilcoxon rank sum test
and the Kruskal-Wallis test for non-parametric analysis of
variance. These tests were utilised to compare the average
percentage of tumour cells in any given specimen that were
positive for TGF-a, AR or CR-1 with tumour size (TI, T2
and T3), axillary lymph node status (NO, axillary node
negative; NI, axillary node positive), histological grade (Gi,
G2 and G3), histology of the tumour (IDC, infiltrating duc-
tal carcinoma; ILC, infiltrating lobular carcinoma), ER and
PR status, BrdU rank, Ki-67 rank and loss of heterozygosity
(LOH) on chromosome 17p, which were assessed in 65 out of
68 cases, and the presence or absence of p53 mutations,.
which was assessed in 56 cases. The same comparison Pear-
son's regression coefficient test was used to assess possible
linear correlations between TGF-o, AR or CR-1 staining
with BrdU, Ki-67, ER status and patient age.
Results
TGF-a mRNA has previously been identified in approxi-
mately 40-70% of infiltrating breast carcinomas (Bates et
al., 1988; Travers et al., 1988; Ciardiello et al., 1989; Barrett-
Lee et al., 1990). To ascertain if there is an equivalent
frequency of TGF-a protein expression in breast lesions and
to determine if there are any differences in the frequency of
TGF-o protein expression between non-malignant and malig-
nant breast tissues, we examined, by ICC, 68 infiltrating
breast carcinomas and 23 non-involved breast tissues that
were adjacent to carcinomas. Of the 68 primary human
breast tumours, 54 (79%) were stained with the R9 rabbit
anti-TGF-a antibody (Table I). Immunoreactivity with the
R9-TGF-uo antibody was generally confined to the carcinoma
cells, since there was very little staining of the surrounding
stroma, smooth muscle or capillary endothelial cells (Figure
lb). Staining was cytoplasmic with some cell membrane reac-
tivity. This staining pattern was specific, since no staining
was detected in parallel sections that had been incubated
either with a similar dilution of preimmune rabbit serum
(data not shown) or with R9 antiserum that had been preab-
sorbed with human TGF-x (Figure la). Heterogeneity of
TGF-ac expression was observed in the carcinoma population.
In eight (12%) tumours over 60% of the carcinoma cells
were stained with R9 anti-TGF-o antibody, while in 18
(26%) tumours 30-60% stained with the antibody and in 28
(41%) less than 30% of the tumour cells expressed
immunoreactive TGF-x (Table I). In contrast to the relatively
high frequency of TGF-x expression in the carcinomas, only
6 (23%) of the 23 non-involved breast tissues that were
adjacent to carcinomas exhibited specific reactivity with the
R9 antibody (Figure Ic). In addition, staining in the non-
involved breast tissue was generally less intense than in the
adjacent tumour cells. Similar to the breast carcinoma cells,
staining was cytoplasmic and was in most instances restricted
to ductal epithelial cells.
The relative distribution and frequency of CR-I expression
Table I Expression of immunoreactive AR, TGF-a and CR-I in human breast
tissues
AR TGF-a CR-1
Mammary epithelium 10/23 (43%) 6/23 (26%) 3/23 (13%)
adjacent to carcinoma
Breast carcinomas 52/68 (77%) 54/68 (79%) 56/68 (82%)
Positive tumour cells
Over 60% 9/68 (13%) 8/68 (12%) 21/68 (31%)
Between 30% and 60% 16/68 (24%) 18/68 (26%) 17/68 (25%)
Less than 30% 27/68 (40%) 28/68 (41%) 18/68 (26%)
Negative 16/68 (23%) 14/68 (21%) 12/68 (18%)
Numbers in parentheses are the percentages of total that were
immunopositive for each protein.906 C.-F. QI et al.
Figure 1 Immunoperoxidase staining of formalin-fixed paraffin-embedded breast tissues using anti-TGF-a R9 antibody (a-c), anti-CR-i antibody (d-f) or anti AR-Ab-I (g-i). In a, d and g, breast carcinoma specimens were reacted with antiserum that had been preabsorbed with either recombinant TGF-a (a), the 17-mer CR-1 synthetic peptide (d), or with the 19-mer AR synthetic peptide (g), x 400 (a, d, g); in b, e and h, serial breast carcinoma sections were reacted with a 1:200 dilution ofthe R9 antibody (b), a 1:400 dilution of the CR-1 antibody (e) or with 10jigml-' AR-Ab-I IgG (h), x 400 (b, e, h); in c, f and i, adjacent non-involved breast epithelium was reacted with a 1:200 dilution of the R9 antibody (c), a 1:400 dilution of the CR-1 antibody (f) or with I0tgml-I AR-Ab-I IgG (i), x200 (f, i) or x400 (c).
in breast tissues was similar to TGF-a (Table I). Of the 68
breast carcinomas, 56 (82%) exhibited intense cytoplasmic
and perinuclear staining with the cripto anti-CR-i antibody
(Figure le), while no staining was observed in tumour sec-
tions after preabsorption of the CR-1 antibody with the
17-mer peptide immunogen (Figure Id). In addition, very
little specific immunoperoxidase staining with the anti-CR-i
antibody was observed within the stroma or within the vas-
cular elements of the carcinomas. As was the case with
TGF-x expression, a marked heterogeneity was observed in
the percentage of carcinoma cells that were stained with the
CR-1 antibody within any one specimen. A greater propor-
tion of the carcinomas expressed CR-1 as compared with
TGF-o: in 21 (31%) carcinomas over 60% of the tumour
cells stained with the CR-1 antibody, whereas in 17 (25%) of
the carinomas in this CR-i-positive group 30-60% of the
cells stained and in 18 (26%) carcinomas less than 30% of
the tumour cells expressed CR-1 (Table I). The frequency of
CR-1 expression in adjacent non-involved breast tissue was
lower than TGF-o expression. Only 3 (13%) of the 23 adja-
cent breast tissues exhibited staining with the CR-1 antibody.
However, in the three specimens that were positive, only a
very weak staining of the ductal epithelial cells was observed
(Figure If).
AR expression in the breast carcinomas was then evaluated
since a specific 1.4 kb mRNA transcript for this growth
factor has recently been shown to be expressed in several
normal human mammary epithelial cell strains and in several
human breast cancer cell lines (Plowman et al., 1990; Cook et
al., 1991; Li et al., 1992; Normanno et al., 1992, 1993). In the
68 breast tumours, 52 (77%) showed specific staining with
the anti-AR Ab-I antibody (Table I). Specific staining was
confined to the carcinoma cells and was both cytoplasmic and nuclear (Figure lh). Preabsorption of the anti-AR IgG fraction with the i9-mer synthetic peptide immunogen abolished the staining (Figure ig). In 13% of the tumours, 60% or more of the carcinoma cells within a given specimen
were stained with the AR-Ab-I antibody, whereas in 24% of
the carcinomas 30-60% of the tumour cells stained, and in
40% of the tumours less than 30% of the carcinoma cells
expressed AR. The frequency of AR expression in adjacent non-involved breast tissue was higher than either TGF-m or
CR-1 expression. Of the 23 adjacent breast tissues, ten (43%) exhibited staining with the anti-AR Ab-I antibody. In non-
involved breast tissues that were positive for AR, less intense
cytoplasmic staining of the ductal epithelial cells was
generally observed as compared with the intensity ofstaining in the carcinoma cells (Figure li). A majority of the breast
carcinomas expressed two or more of these proteins, since 45
(66%) of the 68 breast carcinomas were immunopositive with
all three antibodes,1 whereas only 4 (6%) of the 68 breast
carcinomas were negative for all three proteins. To ascertain if the frequency of expression of TGF-a, CR-1 or AR in the infiltrating breast carcinomas might correlate with any pathological indicators of prognosis, the
percentages of tumour cells that were ICC positive for either
TGF-o, CR-1 or AR within individual carcinoma specimens
were statistically compared by the Wilcoxon rank sum test
with tumour size (T), axillary lymph node involvement (N), histological grade (G), histological type (IDC vs ILC), ER
receptor status, Ki-67 nuclear staining and BrdU incorpora- tion as an index of cell proliferation, LOH on chromosome
17p and the presence ofpoint mutations within the p53 gene (Table II). A variable number of tumours were present withinTGF-a, AMPHIREGULIN AND CRIPTO IN HUMAN BREAST TUMOURS 907
Table II Association of average percentage of breast carcinoma
cells that are positive for AR, TGF-a and CR-1 with
clinicopathological parameters
AR TGF-c CR-1
Parameter n Mean (%) n Mean (%) n Mean (%)
BrdU low 38 30.2 38 30.5 38 42.8
- 0.64a - 0.90 - 0.72
BrdU high 27 23.7 27 30.7 27 40.7
Ki67 low 34 25.1 34 27.0 34 40.3
-0.32 -0.26 -0.71
Ki67 high 31 30.1 31 34.5 31 43.8
P53 normal 40 31.6 40 35.0 40 45.5
-0.008b - 0.08 - 0.19
P53 mutant 16 11.5 16 21.8 16 34.3
P17 normal 39 24.6 39 31.0 39 38.4
-0.10 -0.96 -0.26
P17 LOH 26 31.9 26 30.0 26 47.3
Grade 1 1 60.0 1 90.0 1 50.0
Grade 2 36 24.8 36 30.5 36 42.7
- 0.43 - 0.25 - 0.89
Grade 3 19 22.3 19 31.5 19 47.3
NO 27 29.8 27 29.2 27 38.1
- 0.45 - 0.62 - 0.34
Ni 38 25.9 38 31.5 38 44.7
TI 25 33.0 25 35.2 25 43.2
T2 35 25.0 35 28.2 35 44.8
-0.57 -0.52 -0.13
T3 5 18.0 5 24.0 5 16.0
ER negative 41 26.8 41 30.4 41 39.7
- 0.95 - 0.85 - 0.41
ER positive 24 28.7 24 30.8 24 45.8
IDC 56 24.6 56 31.9 56 44.4
-0.0lb --0.41 -0.10
ILC 9 45.5 9 22.2 9 26.6
aP-values determined by Wilcoxon rank sum test. bStatistically
significant.
each group since several of these parameters were not
evaluated for all 68 of the tumour samples. Histologically, a
majority of the carcinomas, 56 out of 65 (86%), that were
analysed for these prognostic indicators were IDCs, while the
remaining nine (14%) were ILCs. There was no statistically
significant association between the IDC and ILC groups with
respect to the mean number of carcinoma cells that were
immunopositive for either TGF-a or CR-1. However, a
statistically significantly higher percentage of carcinoma cells
expressed AR in the ILC group than in the IDC group (46%
vs 25%; P = 0.01). With the exception of p53 status and
histology, there was no significant association between the
other prognostic factors and the average percentage of
tumour cells within any one specimen that were expressing
any of these three EGF-related proteins (Table II).
The p53 gene maps to chromosome 17p and allelic loss
and/or mutations within exons 4-9 of the gene occur in
nearly 30-50% of breast tumours (Bartek et al., 1990;
Osborne et al., 1991; Mazars et al., 1992). SSCP analysis for
the presence of p53 point mutations within exons 4-9 or
enhanced immunostaining with the anti-p53 antibodies
yielded similar results. SSCP analysis demonstrated that 16
(29%) of the 56 breast tumours that were assessed had one
or more point mutations. More importantly, there was a
statistically significant inverse association between tumours
that had a higher average percentage of tumour cells that
expressed AR and the presence of a p53 mutation(s) (32% vs
12%; P = 0.008). This relationship with p53 mutations was
not observed for TGF-a or CR-1 expression.
Discussion
Abnormal expression of growth factors and their cognate
receptors has been implicated in the pathogenesis of a
number of different types of malignancies (Davidson & Lipp-
man, 1989; Ciardiello et al., 1990a; Gullick, 1990; Osborne &
Arteaga, 1990; Salomon et al., 1990, 1992; Aaronson, 1991;
Sporn & Roberts, 1992). A functional connection exists
between oncogenes and growth factors since some proto-
oncogenes have the capacity to code for growth factors or
growth factor receptors (Aaronson, 1991; Sporn & Roberts,
1992). In this regard, overexpression of the EGF receptor
(c-erbB) coupled with the enhanced production of ligands
that activate this receptor such as TGF-ahave been found in
a number of human tumour cell lines and in several different
types of primary human carcinomas, including breast car-
cinomas, suggesting that a possible autocrine, juxtacrine and/
or paracrine mechanism of growth regulation involving this
receptor signalling pathway might be operative in vitro and in
vivo (Bates et al., 1988; Travers et al., 1988; Ciardiello et al.,
1989, 1990a; Barrett-Lee et al., 1990; Massague, 1990;
Osborne & Arteaga, 1990; Salomon et al., 1990; Aaronson,
1991; Sporn & Roberts, 1992).
The present study is the first to demonstrate by ICC that
not only TGF-o but also two recently discovered members of
the EGF/TGF-a family ofgrowth factors, AR and CR-1, are
expressed at a high frequency and in some cases preferen-
tially in a majority of primary human infiltrating ductal and
lobular breast carcinomas. TGF-a was expressed in 79% of a
small cohort of 68 human primary breast carcinomas that
were examined. Staining was restricted to the cytoplasm and
cell membranes of the tumour epithelial cells. Lundy et al.
(1991) reported TGF-a expression by ICC in 68% of 51
breast carcinomas, while two additional studies have reported
28% and 50% of tumours showing staining for immunoreac-
tive TGF-a protein (Mizukami et al., 1990; Umekita et al.,
1992). This difference in the frequency of TGF-a protein
expression might be due to the use of monoclonal anti-TGF-
a antibodies in these studies as compared with the utilisation
of a polyclonal anti-TGF-.a antibody in the present study.
Formalin fixation might mask specific epitopes in tissues that
monoclonal antibodies would normally recognise, whereas
the polyclonal antibody might be less sensitive to such
changes since multiple epitopes are usually being detected. In
contrast to the high frequency of TGF-aexpression in breast
carcinomas, low levels of TGF-a protein were found in
breast epithelium in that only 26% of adjacent non-involved
mammary epithelium stained positively for TGF-a, and
generally at a lower level of intensity than the corresponding
carcinomas. This finding is in agreement with those of
Barrett-Lee et al. (1990), who found low levels ofexpression
of TGF-a mRNA in 33% (two out of six) of normal human
breast specimens, and with the results of Mizukami et al.
(1990), in which there was little immunoreactive TGF-a in
ten normal breast tissue specimens. In the present study,
there was no significant correlation between the average
percentage of carcinoma cells in any given carcinoma speci-
men that were expressing TGF-a and other clinical
parameters. A similar lack of association between TGF-x
mRNA expression and other clinical and pathophysiological
parameters has been noted in several previous studies (Bates
et al., 1988; Travers et al., 1988; Ciardiello et al., 1989;
Barrett-Lee et al., 1990).
AR is a newly discovered EGF-related growth factor that
is expressed in normal mammary and ovarian epithelial cells
(Cook et al., 1991; Johnson et al., 1991; Li et al., 1992;
Kenney et al., 1993), in several human ovarian, colon and
breast carcinoma cell lines (Ciardiello et al., 1991b; Johnson
et al., 1991, 1992; Cook et al., 1992; Saeki et al., 1992;
Normanno et al., 1993) and in a majority of primary human
colorectal carcinomas (Ciardiello et al., 1991b; Johnson et al.,
1992; Saeki et al., 1992). The present study is the first to
demonstrate the presence of immunoreactive AR in a subset
of primary human breast carcinomas. An enhanced level of
AR expression was observed in 77% of the primary breast
carcinomas that were examined in this study. Lower levels of
expression of AR were detected in 43% of the breast
epithelium specimens that were adjacent to carcinomas.
Recently, Lejeune et al. (1993) have analysed a series of
primary breast tumours for AR expression. They found that
approximately 35% of the breast tumours expressed AR
mRNA and AR protein by immunocytochemistry using an908 C.-F. Ql et al.
anti-AR mouse monoclonal antibody. In their study, there
was no association between AR expression and several prog-
nostic factors with the exception of lymph node status, exp-
ression being more common in lymph node-positive cases
than in lymph node-negative cases. In the present study,
involving both normal and malignant breast tissues, staining
was restricted to the mammary epithelial cells, was in most
cases cytoplasmic and was generally more frequent and
intense in the carcinoma cells than in the surrounding non-
involved breast epithelium. In addition, in the carcinoma
cells, frequent nuclear staining was also observed in a
number of the specimens. Immunolocalisation of AR in the
nucleus has been noted in normal colonic and ovarian sur-
face epithelial cells, in several human breast and colon cancer
cell lines and in colon and ovarian carcinomas (Johnson et
al., 1991, 1992; Saeki et al., 1992; Normanno et al., 1992,
1993). Nuclear localisation of this protein may be due to the
presence of two consensus sequences in the amino-terminal
region that could serve as potential nuclear targeting regions
to translocate the peptide into the nucleus (Plowman et al.,
1990; Modrell et al., 1992). In this respect, addition of
exogenous ['25I]AR to human A431 epidermoid carcinoma
cells or to human HTB-132 breast carcinoma cells leads to
nuclear sequestration of the intact peptide and binding to
two nuclear phosphoproteins (Modrell et al., 1992). This may
not be unique to AR since other growth factors such as
HB-EGF, nerve growth factor, interleukin 1, basic fibroblast
growth factor (bFGF) and the int-2 FGF-related protein also
possess nuclear localisation sequences and can be detected in
the nucleus (Imamura et al., 1990; Powell & Klagsbrun, 1991;
Higashiyama et al., 1992; Acland et al., 1993; Rakowicz-
Szulczynska, 1993). In this regard, multiple forms of bFGF
have been found in the nuclei of target cells, and deletion of
the amino terminal nuclear retention sequences from either
bFGF or from AR can abolish their mitogenic activity
(Imamura et al., 1990; Powell & Klagsbrun, 1991; Kimura,
1993).
The inverse association between the average number of
carcinoma cells that express AR and the p53 status of the
breast tumour is intriguing. A significantly greater percentage
of carcinoma cells in breast tumours that contained a normal
p53 gene express AR than in tumour specimens that pos-
sessed p53 mutations. Inactivation of p53 tumour-suppressor
activity in human breast tumours can occur by missense
mutations in one allele, which is frequently followed by LOH
or by a reduction to homozygosity in the second allele (Cal-
lahan & Campbell, 1989; Osborne et al., 1991; Mazars et al.,
1992; Ullrich et al., 1992). It is possible that the wild-type
p53 protein might positively regulate the expression of AR.
In this regard, wild-type p53 can repress the promoter for
interleukin 6, another autocrine growth factor (Santhanam et
al., 1991). It is also of interest to note that there is a
significant association in primary breast carcinomas between
EGF receptor levels and the presence of p53 mutations,
suggesting that a mutant p53 protein might up-regulate EGF
receptor expression (Horak et al., 1991; Poller et al., 1992).
Finally, expression of p53 mutations in one study was found
to be rare in infiltrating lobular carcinomas (Poller et al.,
1992), which may relate to the findings in the present study
demonstrating that the average percentage of carcinoma cells
that were expressing AR in individual tumours was signifi-
cantly higher in infiltrating lobular carcinomas, which tend to
be histologically more differentiated, than in infiltrating duc-
tal carcinomas. A similar situation has been found in human
primary colorectal tumours, in which a higher frequency of
AR expression was detected in well-differentiated carcinomas
than in poorly differentiated tumours (Saeki et al., 1992).
Expression of CR-I has been detected in only a limited
number of malignant cells, such as undifferentiated mouse
and human embryonal carcinoma cells, several human gast-
ric, colon and breast cancer cell lines and primary human
colorectal and gastric carcinomas (Ciccodicola et al., 1989,
1991b; Kuniyasu et al., 1991; Saeki et al., 1992; Normanno et
al., 1993). Eighty-two per cent of the breast carcinomas were
immunopositive for CR-1, while only 13% of the adjacent
non-involved breast epithelial specimens were reactive with
the anti-CR-1 antibody. These values are very close to the
frequency of CR-1 expression that was observed in colorectal
tumours and in adjoining, non-involved colonic mucosa. The
antibody preferentially stained the carcinoma cells and
showed cytoplasmic reactivity in most cases. There was no
significant correlation between the average number of car-
cinoma cells that exhibited CR-1 reactivity in any given
carcinoma specimen and several clinical parameters that were
examined. However, the greater differential expression of
CR-1 in breast carcinomas relative to TGF-a and AR, which
were generally expressed at a higher frequency than CR-1 in
the non-involved breast epithelium, suggests that CR-1 may
serve as a potential breast tumour marker. The significance
of this observation is unclear since a recombinant protein is
not available to determine whether the CR-1 protein has any
biological activity. However, preliminary evidence using
refolded peptides that correspond to the EGF-like domain of
the CR-1 protein has demonstrated that these peptides are
able to stimulate the proliferation of non-transformed
184A1N4 human mammary epithelial cells and several
human breast cancer cell lines (Brandt et al., in preparation).
Coexpression of TGF-a, AR and CR-1 occurred in 66% (45
out of 68) of the breast carcinomas, while only 6% (4 out of
68) of the tumours failed to express all three proteins. The
significance of the high frequency of coexpression of three
EGF-related peptides in breast carcinomas has yet to be
clarified. However, this is apparently not unique to breast
carcinomas, since a similar situation with respect to the
coexpression of TGF-a, AR and CR-1 mRNA transcripts
and coexpression of immunoreactive AR and CR-1 proteins
is found in human colorectal carcinomas (Ciardiello et al.,
1991b; Cook et al., 1992; Saeki et al., 1992). At least two of
these three EGF-related peptides, TGF-a and AR, are bona
fide growth factors that function exclusively through the
EGF receptor (Massague, 1990; Plowman et al., 1990;
Salomon et al., 1990; Johnson et al., 1993). The apparent
redundancy in the expression in mammary epithelial cells of
two structurally and biologically related peptides suggests
that these peptides may be involved in the regulation of
additional biological properties other than cell proliferation
such as differentiation. This may be the case since in normal
colon specimens immunoreactive AR protein is not found in
the proliferative stem cell population of the crypts but is
preferentially expressed in the terminally differentiated, non-
proliferative columnar and secretory epithelial cells of the
villous mucosa and is found at a higher frequency in better
differentiated colon carcinomas (Johnson et al., 1992; Saeki
et al., 1992).
The authors would like to express their gratitude to Dr Beatrice
Langton, Berlex Biosciences, for generously providing the anti-TGF-
a R9 antibody.
Abbreviations: EGF, epidermal growth factor; TGF-a, transforming
growth factor a; AR, amphiregulin; HB-EGF, heparin-binding EGF-
like growth factor; CR-1, cripto-1; ICC, immunocytochemistry;
LOH, loss of heterozygosity; IgG, immunoglobulin G; KLH,
keyhole limpet haemocyanin; kb, kilobase; RFLP, restriction frag-
ment length polymorphism; SSCP, single-strand conformation
polymorphism; cDNA, complementary DNA; PCR, polymerase
chain reaction; BrdU, bromodeoxyuridine; DCC, dextran-coated
charcoal; ER, estrogen receptor, PR, progesterone receptor; IDC,
infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma;
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